Skip to content

Glucotrack to Showcase Implantable Continuous Blood Glucose Monitoring at ADA 2026

Glucotrack, Inc. will present its innovative implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans. The technology promises direct blood measurements, multi-year longevity, and eliminates on-body wearables. Glucotrack has submitted an IDE application to the FDA and has published peer-reviewed studies supporting its sensor design, highlighting a significant step towards initiating a U.S. clinical study.

RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.